Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Newly-approved therapy provides improved quality of life for midgut neuroendocrine tumour patients

Midgut neuroendocrine tumours are a rare type of cancer that develops in the small intestine and colon.

Roughly 12,000 people are diagnosed with this disease each year.

In January, the United Stated Food and Drug Administration approved Lutathera, a first-of-its-kind peptide receptor radionuclide therapy.

The injection consists of a somatostatin analog combined with a radioactive isotope that directly targets neuroendocrine tumour cells.

Dr. Jonathan Strosberg, head of Neuroendocrine Tumour Program at Moffitt "Treatment options have been limited for patients with neuroendocrine tumours and toxicities of treatment can often outweigh the benefit.

Our studies have shown Lutathera is an effective option to treat tumour progression and also provide patients with a better quality of life," said Jonathan R. Strosberg, M.D., head of the Neuroendocrine Tumour Program at Moffitt Cancer Center.

The Journal of Clinical Oncology published new data from the NETTER-1 clinical trial highlighting the impact of Lutathera on patients' quality of life.

Strosberg notes the importance of this issue, given the relatively long durations of treatments and overall survival compared to other malignancies.

The results showed that treatment with Lutathera provides significantly longer time to deterioration of quality of life for patients compared to those treated with octreotide LAR alone.

Patients in the study were given questionnaires every three months until tumour progression.

Quality of life was measured by global health status, physical functioning, role functioning, fatigue, pain, diarrhoea, disease-related worries and body image.

The time of deterioration was defined as the period of time from the patient's first questionnaire response until their quality of life score declined ten or more points.

Patients treated with Lutathera reported improvement in many of the typical side effects, such as fatigue, pain and diarrhoea.

Differences in the median time to deterioration were 28.8 months versus 6.1 months for global health status, and 25.2 months versus 11.5 months for physical functioning.

Source: H. Lee Moffitt Cancer Center & Research Institute

0

Comments

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence